Career history of James Smith
Former positions of James Smith
| Companies | Position | Start | End |
|---|---|---|---|
| SIERRA ONCOLOGY, INC. | Investor Relations Contact | 22/10/2014 | 01/12/2020 |
| Corporate Officer/Principal | 01/12/2020 | 01/07/2022 | |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Investor Relations Contact | 01/01/2011 | 01/01/2014 |
| Public Communications Contact | 01/01/2011 | 01/01/2014 | |
| SQI DIAGNOSTICS INC. | Corporate Officer/Principal | 01/01/2014 | - |
Training of James Smith
| Queen's University | Graduate Degree |
| LaTrobe University | Masters Business Admin |
Statistics
International
| Canada | 3 |
| United Kingdom | 2 |
| United States | 2 |
Operational
| Investor Relations Contact | 2 |
| Corporate Officer/Principal | 2 |
| Public Communications Contact | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SQI DIAGNOSTICS INC. | Health Technology |
| Private companies | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Stock Market
- Insiders
- James Smith
- Experience
